Articles tagged with Psoriasis
Research found that psoriasis patients had high levels of blood vessel inflammation, even at low cardiovascular risk. The most extensive forms of psoriasis were associated with a 51% increase in blood vessel inflammation.
A multicenter clinical trial led by Mount Sinai researchers found that brodalumab achieved a 100 percent reduction in psoriasis symptoms, exceeding the results of ustekinumab. The study demonstrated that targeting the IL-17 receptor is highly effective in treating moderate to severe plaque psoriasis.
A study published in JAMA Dermatology found that psoriasis is associated with a higher risk of major depression, regardless of severity. Patients with psoriasis reported daily functional impairment more frequently than those without the condition.
A new psoriasis drug called guselkumab has been shown to be more effective than the current standard of care in treating moderate-to-severe psoriasis. The study found that 81% of patients taking a 200-mg dose of guselkumab had cleared or minimal psoriasis after 40 weeks.
Eleven early-career physicians received one-year, $50,000 fellowships to study various aspects of psoriasis and psoriatic arthritis. The fellowships aim to increase the number of scientists expertly treating these conditions.
A large population study found an increased risk of developing Psoriatic Arthritis among psoriasis patients exposed to physical trauma, particularly bone and joint traumas. The study suggests further investigation into the complex factors leading to arthritis in psoriasis patients may lead to modified risk.
A new psoriasis drug, ixekizumab, has shown significant improvement in treating the condition, with 40% of patients clearing all symptoms within 12 weeks. The treatment was found to be more effective than a placebo or widely used drug etanercept.
The National Psoriasis Foundation has awarded five Translational Research Grants to researchers investigating the causes of psoriasis and psoriatic arthritis. The grants will support studies on genetic risk factors, gut bacteria, and targeted treatments for these conditions.
The National Psoriasis Foundation has awarded eight researchers $75,000 each to study the causes of psoriasis and develop new treatments. The grants will support research into various aspects of psoriasis, including genetic mutations, skin stem cells, and inflammatory proteins.
Researchers report significant recovery after a single dose of an experimental treatment targeting interleukin-23, a key immune signaling protein in psoriasis. The study found nearly all patients experienced dramatic improvement in their symptoms, with an average 80% reduction in skin lesions.
Scientists have identified Interleukin 4 (IL-4) as a promising treatment for psoriasis, a chronic autoimmune disease. By inhibiting specific immune cells, IL-4 reduces inflammation and improves skin conditions in patients.
A recent study has identified a gene that increases the risk of developing psoriatic arthritis, a condition where patients often experience both skin psoriasis and joint pain. The researchers found genetic changes that distinguish PsA from its counterpart psoriasis.
A study discovered that genetic variations associated with psoriasis and Crohn's disease are extremely old, predating the evolution of Neanderthals. The research suggests that these genetic features may have played a role in the health and survival of our ancient ancestors.
Researchers identified four proteins - stefin A1, slc25a5, serpinb3b, and KLK6 - that appear most likely to contribute to psoriasis. These findings advance efforts to understand the disease's causes and develop treatments.
Psoriasis affects 3.2% of the US population, with annual costs ranging from $51.7 billion to $135 billion, including direct healthcare costs, absenteeism, and intangible effects on mental health.
A review article estimates the annual US cost of psoriasis in 2013 to be between $112 billion and $135 billion. The study found direct costs ranging from $51.7 billion to $63.2 billion, while indirect costs due to absenteeism or reduced work capacity ranged from $23.9 billion to $35.4 billion.
A UC Irvine-led study has revealed that a gene called grainyhead triggers a repair pathway for psoriasis lesions. The researchers found that targeting this mechanism may lead to pharmaceutical products that limit the itchy, painful lesions of psoriasis.
Researchers found that patients with severe psoriasis are more likely to have uncontrolled hypertension, and the likelihood of hypertension increases with greater psoriasis severity. The study used objective measures of psoriasis severity for the first time, providing new insights into the link between psoriasis and blood pressure.
Research reveals a significant association between psoriasis severity and uncontrolled hypertension, with patients having the greatest likelihood of uncontrolled hypertension experiencing more severe skin conditions. The study's findings suggest a need for effective management of blood pressure in these patients.
Researchers found that plasmacytoid dendritic cells trigger early psoriasis, while Langerhans cells help regulate the immune response. Modulating dendritic cell composition may lead to new psoriasis treatments.
The National Psoriasis Foundation has awarded 13 fellowships to early-career physicians to study psoriasis and its impact on patients. The fellowships aim to increase the number of scientists studying and treating psoriasis, with a focus on developing new treatments and improving patient outcomes.
The National Psoriasis Foundation has awarded $1.05 million in research grants to 13 scientists studying new treatments and a cure for psoriasis and psoriatic arthritis. The grants will support projects focused on translating laboratory findings into improved treatments and methods for managing the diseases.
A study published in JAMA Dermatology found that women with long-term hypertension are at a higher risk of developing psoriasis. Long-term use of beta-blocker medication also increases the risk of psoriasis. The study analyzed data from 77,728 women and found a significant association between hypertension and psoriasis risk.
A 25-year-old patient with alopecia universalis has successfully regrown a full head of hair, including eyebrows and facial hair, after receiving the novel treatment. The patient's condition was previously untreatable, but the new treatment using FDA-approved drug tofacitinib citrate reversed his disease.
A study found that nearly three-quarters of PsA patients were on doses lower than recommended for infliximab, while a third of those on adalimumab had trough concentrations below the optimal level. Despite this, low dosing showed reasonable efficacy in both treatments.
Researchers discovered that stimulating AhR in skin cells reduces inflammation in psoriasis patients, a potential new treatment approach for chronic inflammatory skin disorders. The findings suggest a novel strategy for treating psoriasis, combining immune system modulation with AhR stimulation.
Researchers at CNIO have identified two novel treatments for psoriasis, one targeting S100A9 and the other inhibiting miR-21, which show promise in reducing side effects. These discoveries offer new hope for patients suffering from this chronic disease.
Researchers at King's College London have discovered a new gene (PIM1) that could be an effective target for innovative treatments and therapies for psoriasis. The study highlights the role of PIM1 and the IL-22 cytokine in skin inflammation, suggesting a direct link between these two.
Researchers have developed a novel topical therapy targeting genetic abnormalities in deeper skin layers to improve psoriasis symptoms. The new treatment, Dual-F-NALP, has shown promising results by reducing inflammation and suppressing immune hypersensitivity.
Researchers analyzed 21,309 Chinese individuals and identified only two independent low-frequency coding variants with moderate effect on disease risk. These findings suggest that the overall genetic risk for psoriasis is largely driven by other factors, contradicting previous assumptions about the role of coding variants.
Patients with moderate to severe psoriasis are at increased risk of developing chronic kidney disease, particularly those with severe disease. Closer monitoring and careful consideration of medications are recommended for this patient population.
Researchers at Scripps Research Institute have identified key signaling proteins that contribute to the development of inflammatory diseases such as rheumatoid arthritis and psoriasis. By targeting these proteins, a new class of anti-inflammatory therapy may be developed.
A psoriasis researcher has received a third NIH grant to explore the nervous system's involvement in psoriasis. The study aims to identify new targets for drug development and improve patient care by investigating nerve-derived peptides critical to sustaining the disease.
A Penn study found that psoriasis patients with more severe skin disease are at higher odds of having major medical diseases, including lung disease, heart problems, and kidney issues. The researchers identified a common pathway involving TH-1 cytokines promoting inflammation and insulin resistance.
The National Psoriasis Foundation has awarded the inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship to Zelma Chiesa, a third-year dermatology resident. Through this one-year fellowship, Chiesa will investigate treatments and health risks of psoriasis, aiming to predict skin clearance and cardiovascular events.
The National Psoriasis Foundation has awarded twelve fellowships totaling nearly half a million dollars to researchers working to cure psoriasis and psoriatic arthritis. The fellowships will support studies on the impact of diet, exercise, and lifestyle on psoriasis severity and treatment outcomes.
Psoriatic arthritis patients treated with ustekinumab showed significant and sustained improvements in signs and symptoms, even in those previously treated with biologic agents. The treatment was well-tolerated with no deaths or serious adverse events.
Six top scientists received funding for projects aiming to discover new treatments and a cure for psoriasis and psoriatic arthritis. The National Psoriasis Foundation awarded $450,000 in research grants to support promising research projects.
A new study from Umea University finds that men with more severe psoriasis receive more frequent and expensive treatment, contributing to higher healthcare costs. The research analyzed data from over 2,200 Swedish patients and found a significant difference in disease severity between men and women.
Researchers at Ben-Gurion University of the Negev and Teva Pharmaceutical Industries Ltd. have developed a promising drug candidate to treat psoriasis. The engineered receptor effectively reduces inflammatory signals in mice models, showing potential for a viable treatment for severe psoriasis patients.
A large international study shows that children with psoriasis are twice as likely to be overweight or obese as healthy children, and US children with severe psoriasis have four times the odds. Lifestyle interventions, such as increasing exercise and decreasing caloric intake, are crucial to reducing the risk of metabolic diseases.
A study of children with psoriasis found a strong association between the condition and excess adiposity, including waist circumference and waist-to-height ratio. Children with psoriasis are more likely to be overweight or obese, increasing their risk for metabolic complications.
A systematic review and meta-analysis of 27 studies found a strong correlation between psoriasis and an increased risk of developing diabetes. Patients with severe psoriasis are nearly twice as likely to have diabetes compared to the general population.
A study published in the Journal of Clinical Investigation found that mice lacking interleukin-36 (IL-36) were protected from psoriasis-like skin inflammation. This suggests that targeting IL-36 could be a promising approach for treating psoriasis.
Case Western Reserve University researcher Nicole Ward is leading a study to identify the mechanistic link between psoriasis and heart attack/stroke. The study aims to provide first-ever evidence that cell-specific events in psoriasis can be targeted for treatment, potentially improving cardiovascular disease outcomes.
Patients with psoriasis are at higher risk of new-onset diabetes mellitus due to chronic inflammation. The study found that the risk increases with severity of psoriasis, with patients having severe psoriasis being more than twice as likely to develop diabetes.
A retrospective study published in Archives of Dermatology found that patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a significantly lower risk of heart attack compared to those not treated with TNF inhibitors. The study included 8,845 patients and adjusted for other MI risk factors.
Researchers have found a key molecule, REG3A, highly expressed in skin cells during psoriasis and wound repair, causing abnormal cell proliferation. Blocking REG3A delays wound healing and clears up psoriasis-like pathology in mice, offering potential therapeutic targets.
Researchers have identified a molecule called regenerating islet-derived protein 3-alpha (REG3A) that is highly expressed in skin cells during psoriasis and wound-healing, but not under normal skin conditions. Inhibiting REG3A may clear up psoriasis and slow down wound-healing.
Researchers found that patients with psoriasis are at increased risk of developing Type 2 Diabetes, even without common risk factors like obesity. The study estimated an additional 115,500 people will develop diabetes each year due to the risk posed by psoriasis.
A population-based study from the UK suggests that psoriasis is associated with an increased risk of developing type 2 diabetes. The study found that patients with severe psoriasis were more likely to receive prescription diabetic therapy and had a trend towards being prescribed insulin.
A study published in Archives of Dermatology suggests that vigorous physical activity is associated with a reduced risk of psoriasis in US women. Participating in at least 20.9 MET-hours of vigorous exercise per week may reduce the risk by 25-30%. The study found no association between walking and psoriasis risk.
The National Psoriasis Foundation has awarded a record $2.06 million in grants to 26 scientists studying psoriasis and psoriatic arthritis, aiming to advance knowledge and lead to new treatments. The foundation's mission is to find a cure for these autoimmune diseases through research, advocacy, and education.
Researchers discovered a causal link between chronic skin inflammation and cardiovascular disease, with aggressive reversal of psoriasis reducing the risk. A mouse model demonstrated that persistent inflammation leads to vessel wall inflammation and blood clot formation, which can increase stroke or heart attack risk.
Researchers found that PAX5 stabilizes MYC protein levels in B cells, correlating with poor patient survival. Additionally, STIM1 regulates calcium signaling to control fat preference, while IL-12 production is decreased in diabetic patients with increased infection risk.
Researchers have identified a rare gene mutation in the CARD14 gene that is directly linked to plaque psoriasis, accounting for 80% of all cases. The discovery may lead to more effective treatments and sheds light on the genetic pathway underlying the condition.
A clinical study found that treating psoriasis with adalimumab significantly decreased vascular inflammation, a major risk factor for cardiovascular disease. The study also showed a 51% decrease in C-reactive protein levels among treated patients, compared to a 2% decrease in the control group.
Patients with moderate to severe psoriasis prioritize treatment location, probability of benefit, and method of delivery over treatment outcome attributes. The study highlights the significance of incorporating patient preferences in shared decision-making to optimize treatment adherence and outcomes.
Researchers found that psoriasis patients have a higher number of smaller LDL particles and reduced HDL efflux capacity compared to controls, suggesting an underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.
A study found that treatment approaches for pediatric psoriasis differ by physician specialty and patient age, with topical medications being the primary treatment for mild cases. The researchers highlight the need for standardized guidelines to address the condition in children.